Vanadate activates membranous nonreceptor protein tyrosine kinase in rat adipocytes

Diabetes

Volumn 46, Issue 11, 1997, Pages 1684-1690

  Elberg, Gerard ^a   He, Zhibin ^a   Li, Jinping ^a   Sekar, Natesampillai ^a   Shechter, Yoram ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; STAUROSPORINE; VANADIC ACID;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GLUCOSE HOMEOSTASIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

EID: 0030724164     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.46.11.1684     Document Type: Article

References (42)

1. Shisheva A, Shechter Y: A cytosolic protein tyrosine kinase in rat adipocytes. Febs Lett 300:93-96, 1992
2. Green A: The insulin-like effect of sodium vanadate on adipocyte glucose transport is mediated at a post-insulin-receptor level. Biochem J 238:663-669, 1986
3. Fantus GI, Kadota S, Deragon G, Foster B, Posner BI: Pervanadate [peroxide(s) of vanadate] mimics insulin action in rat adipocytes via activation of the insulin receptor tyrosine kinase. Biochemistry 28:8864-8871, 1989
4. Stroat HV, Vicario PP, Superstein R, Slater EE: The insulin-mimetic effect of vanadate is not correlated with insulin receptor tyrosine kinase activity nor phosphorylation in mouse diaphragm. Endocrinology 124:1918-1924, 1989
5. D'Onofrio F, Le MQU, Chiasson J-L, Srivastava AK: Activation of mitogen activated protein (MAK) kinases by vanadate is independent of insulin receptor autophosphorylation. FEBS Lett 340:269-275, 1994
6. Pandey SK, Chiasson J-L, Srivastava AK: Vanadium salts stimulate mitogen-activated protein (MAP) kinases and ribosomal S6 kinases. Mol Cell Biochem 153:69-78, 1995
7. Shisheva A, Shechter Y: Role of cytosolic tyrosine kinase in mediating insulin-like actions of vanadate in rat adipocytes. J Biol Chem 268:6463-6469, 1993
8. Shisheva A, Shechter Y: Quercetin selectively inhibits insulin receptor function in vitro and the bioresponses of insulin and insulinomimetic agents in rat adipocytes. Biochemistry 31:8059-8063, 1992
9. Rosen OM: After insulin binds. Science 237:1452-1458, 1987
10. White MF, Shoelson SE, Keutmann H, Kahn CR: A cascade of tyrosine autophosphorylation in the β-subunit activates the phosphotransferase of the insulin receptor. J Biol Chem 263:2969-2980, 1988
11. Elberg G, Li J, Shechter Y: Vanadium activates or inhibits receptor and non-receptor protein tyrosine kinases in cell-free experiments, depending on its oxidation state. J Biol Chem 269:9521-9527, 1994
12. Elberg G, Li J, Leibovitch A, Shechter Y: Non-receptor cytosolic protein tyrosine kinases from various rat tissues. Biochim Biophys Acta 1269:299-306, 1995
13. Rodbell M: Metabolism of isolated fat cells. I. Effects of hormone on glucose metabolism and lipolysis. J Biol Chem 238:375-380, 1964
14. Gliemann J, Osterlind K, Vinten J, Gammeltoft S: A procedure for measurement of distribution spaces in isolated fat cells. Biochim Biophys Acta 286:1-9, 1972
15. Shechter Y: Evaluation of adenosine or related nucleosides as physiological regulators of lipolysis in adipose tissue. Endocrinology 110:1579-1583, 1982
16. Kelly LK, Ruderman NB, Chen KS: Phosphatidylinositol-3-kinase in isolated rat adipocytes. J Biol Chem 267:3423-3428, 1992
17. Shisheva A, Leithner O, Shechter Y: A novel approach for evaluating tyrosine kinase activity based on the radioimmunological determination of phosphotyrosine. J Biochem Biophys Methods 23:307-314, 1991
18. Bradford MM: A rapid and sensitive method for the quanutation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72:248-254, 1976
19. Shechter Y: Trifluoperazine inhibits insulin action on glucose metabolism in fat cells without affecting inhibition of lipolysis. Proc Natl Acad Sci USA 81:372-331, 1984
20. Amir S, Sasson S, Kaiser N, Meyerovitch J, Shechter Y: Polymxin B is an inhibitor of insulin-induced hypoglycemia in the whole animal model: studies on the mode of inhibitory action. J Biol Chem 262:6663-6667, 1987
21. Shechter Y, Yaish P, Chorev M, Gilon C, Braun S, Levitzki A: Inhibition of insulin-dependent lipogenesis and anti-lipolysis by protein-tyrosine kinase inhibitors. EMBO J 8:1671-1676, 1989
22. Li J, Elberg G, Shechter Y: Phenylarsine oxide and vanadate: apparent paradox of inhibition of protein phosphotyrosine phosphatases in rat adipocytes. Biochim Biophys Acta 1312:223-230, 1996
23. Okada T, Kawano Y, Sakakibara T, Hazeki O, Michio U: Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes: studies with a selective inhibitor wortmannin. J Biol Chem 269:3568-3573, 1994
24. Li J, Elberg G, Sekar N, He Z, Shechter Y: Antilipolytic actions of vanadate and insulin in rat adipocytes mediated by distinctly different mechanisms. Endocrinology 138:2274-2279, 1997
25. Giorgetti S, Ballotti R, Kowalski-Chauvel A, Taftare S, Van Obberghen E: The insulin and insulin-like growth factor-I receptor substrate IRS-1 associates with and activates phosphatidylinositol 3-kinase in vitro. J Biol Chem 268:7358-7364, 1993
26. Ruderman NB, Kapeller R, White MF, Cantley LC: Activation of phosphatidylinositol 3-kinase by insulin. Proc Natl Acad Sci USA 87:1411-1415, 1990
27. Skolnik EY, Lee CH, Batzer A, Vicentini LM, Zhou M, Daly R, Myers MJ Jr., Backer JM, Ullrich A, White MF, Schlessinger J: The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and SHC: implications for insulin control of ras signalling. EMBO J 12:1929-1936, 1993
28. src protein. Mol Cell Biol 9:1651-1658, 1989
29. Isakoff S, Taha C, Rose E, Marcusohn J, Klip A, Skolnik E: The inability of phosphatidylinositol 3-kinase activation to stimulate GLUT4 translocation indicates additional signaling pathways are required for insulin-stimulated glucose uptake. Proc Natl Acad Sci USA, 92:10247-10251, 1995
30. Heller-Harrison RA, Morin MM, Guilherme A, Czech MD: Insulin-mediated targeting of phosphatydylinositol 3-kinase to GLUT4-containing vesicles. J Biol Chem 271:10200-10204, 1996
31. Brichard SM, Okitolonda W, Henquin JC: Long term improvement of glucose homeostasis by vanadate treatment of diabetic rats. Endocrinology 123:2048-2053, 1988
32. Brichard SM, Ongemba LN, Girard J, Henquin JC: Tissue-specific correction of lipogenic enzyme gene expression in diabetic rats given vanadate. Diabetologia 37:1065-1072, 1994
33. Brichard SM, Pottier AM, Henquin JC: Long-term improvement of glucose homeostasis by vanadate in obese hyperinsulinemic fa/fa rate. Endocrinology 125:2728-2732, 1989
34. Brichard SM, Bailey CJ, Henquin JC: Marked improvement of glucose homeostasis in diabetic ob/ob mice given oral vanadate. Diabetes 39:1326-1332, 1990
35. Meyerovitch J, Rothenberg P, Shechter Y, Bonner-Weir S, Kahn CR: Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. J Clin Invest 87:1286-1294, 1990
36. Brichard SM, Ongemba LN, Henquin JC: Oral vanadate decreases muscle insulin resistance in obese fa/fa rats. Diabetologia 35:522-527, 1992
37. Brichard SM, Assimacopoulos JF, Jeanrenaud B: Vanadate treatment markedly increases glucose utilization in muscle of insulin resistant fa/fa rats without modifying glucose-transporter expression. Endocrinology 131:311-317, 1992
38. Pugazhenthi S, Hussain A, Yu B, Brownsey WR, Angel JF, Khandelwal RL: Vanadate induces normolipidemia and a reduction in the levels of hepatic lipogenlc enzymes in obese Zucker rats. Mol Cell Biochem 153:211-215, 1995
39. Khandelwal RL, Pugazhenthi S: In vivo effects of vanadate on hepatic glycogen metabolizing and lipogenic enzymes in insulin-dependent and insulin-resistant diabetic animals. Mol Cell Biochem 153:87-94, 1995
40. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR: Metabolic effects of sodium metavanadate in humans with insulin-dependent and non-insulin-dependent diabetes mellitus in vivo and in vitro studies. J Clin Endocrinol Metab 80:3311-3320, 1995
41. Cohen N, Halberstam M, Shlimovich P, Chang CJ, Sharmoon H, Rossetti L: Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 95:2501-2509, 1995
42. Halberstam M, Cohen N, Shlimovitch P, Rossetti L, Shamoon H: Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes 45:659-666, 1996